AGP Executive Report
Last update: 11 hours agoMedical Safety & Recalls: Sun Pharma recalled multiple eye drops in India after contamination concerns, halting distribution and asking distributors to stop sales and return stock. Clinical Trials & Devices: XVIVO won FDA approval for additional patient enrollment in the US PRESERVE CAP study for its heart assist transport device, with CMS continued cost recovery to support ongoing data collection. Cancer Screening Systems: New Zealand’s cervical screening programme review found nearly a million notifications weren’t sent due to design and process flaws, including “inactive” eligibility rules and incorrect postal details. Public Health & Outbreaks: States Newsroom reports outbreaks are stressing the US public health system amid funding cuts and vaccine resistance. Mental Health Policy: A column argues there are no “shortcuts” to solving the youth mental health crisis and warns against relying on bans alone. Wearables & Health Tech: Apple is reportedly exploring health and fitness tracking in future smart glasses and AR headsets via onboard sensors. Regulatory/Workplace Health: Moldova is drafting updates to simplify occupational health and safety requirements for executives handling worker protection. Biopharma Pipeline: Oculis received positive FDA pre-IND feedback for Privosegtor in acute MS relapses, and Aravax’s PVX108 won FDA Fast Track for peanut allergy.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
